TW202339795A - 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法 - Google Patents

用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法 Download PDF

Info

Publication number
TW202339795A
TW202339795A TW111143328A TW111143328A TW202339795A TW 202339795 A TW202339795 A TW 202339795A TW 111143328 A TW111143328 A TW 111143328A TW 111143328 A TW111143328 A TW 111143328A TW 202339795 A TW202339795 A TW 202339795A
Authority
TW
Taiwan
Prior art keywords
uveitis
antibody
subject
various embodiments
weeks
Prior art date
Application number
TW111143328A
Other languages
English (en)
Chinese (zh)
Inventor
佩斯阿瓦利 史瑞德哈那桑達瑞
羅納德 布加
卡連 朱
瓦萊利 寇普迪特甘地
克里斯汀 艾利克森
多明尼克 瑪利米格納德
拉斐爾 瓦羅納
羅伯特 維堤
Original Assignee
法商賽諾菲生物技術公司
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲生物技術公司, 美商再生元醫藥公司 filed Critical 法商賽諾菲生物技術公司
Publication of TW202339795A publication Critical patent/TW202339795A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111143328A 2015-11-03 2016-11-03 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法 TW202339795A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562250269P 2015-11-03 2015-11-03
US62/250,269 2015-11-03
EP16306166 2016-09-14
EP16306166.6 2016-09-14
US201662408391P 2016-10-14 2016-10-14
US62/408,391 2016-10-14

Publications (1)

Publication Number Publication Date
TW202339795A true TW202339795A (zh) 2023-10-16

Family

ID=57018106

Family Applications (3)

Application Number Title Priority Date Filing Date
TW111143328A TW202339795A (zh) 2015-11-03 2016-11-03 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法
TW105135684A TWI729022B (zh) 2015-11-03 2016-11-03 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法
TW110117779A TWI786636B (zh) 2015-11-03 2016-11-03 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW105135684A TWI729022B (zh) 2015-11-03 2016-11-03 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法
TW110117779A TWI786636B (zh) 2015-11-03 2016-11-03 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法

Country Status (13)

Country Link
US (2) US10968278B2 (https=)
EP (1) EP3371224B1 (https=)
JP (4) JP7272794B2 (https=)
KR (2) KR20260036589A (https=)
CN (1) CN108473583A (https=)
AU (2) AU2016348418B8 (https=)
BR (1) BR112018008900A8 (https=)
CA (1) CA3003874A1 (https=)
IL (1) IL319993A (https=)
MX (2) MX2018005589A (https=)
SG (1) SG11201803654TA (https=)
TW (3) TW202339795A (https=)
WO (1) WO2017079443A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
IL319993A (en) * 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
AU2019329958B2 (en) 2018-08-29 2025-05-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
CN116528892A (zh) * 2020-10-28 2023-08-01 再生生物股份有限公司 用于眼部适应症的载体化抗TNF-α抗体
AU2023369998A1 (en) * 2022-10-24 2025-01-23 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
WO2009140348A2 (en) * 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠＬ-1β 관련 병태의 치료 방법
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
BR112015010360A8 (pt) * 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014352801B2 (en) 2013-11-22 2020-05-28 Regeneron Pharmaceuticals, Inc. Compositions for the treatment of rheumatoid arthritis and methods of using same
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
IL319993A (en) 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Also Published As

Publication number Publication date
WO2017079443A1 (en) 2017-05-11
US20170166646A1 (en) 2017-06-15
EP3371224A1 (en) 2018-09-12
JP2021193120A (ja) 2021-12-23
BR112018008900A8 (pt) 2019-02-26
CN108473583A (zh) 2018-08-31
WO2017079443A8 (en) 2017-07-06
JP7272794B2 (ja) 2023-05-12
KR20260036589A (ko) 2026-03-17
AU2016348418A8 (en) 2023-10-19
IL319993A (en) 2025-06-01
TWI786636B (zh) 2022-12-11
MX2022011972A (es) 2022-10-20
BR112018008900A2 (pt) 2018-11-06
US10968278B2 (en) 2021-04-06
TW201729828A (zh) 2017-09-01
TW202138001A (zh) 2021-10-16
EP3371224B1 (en) 2026-04-29
AU2016348418A1 (en) 2018-06-21
US20210301027A1 (en) 2021-09-30
AU2016348418B2 (en) 2023-10-12
AU2023233110A1 (en) 2023-10-05
AU2016348418B8 (en) 2023-10-19
SG11201803654TA (en) 2018-05-30
KR102930886B1 (ko) 2026-02-25
JP2023062062A (ja) 2023-05-02
CA3003874A1 (en) 2017-05-11
JP7581399B2 (ja) 2024-11-12
TWI729022B (zh) 2021-06-01
MX2018005589A (es) 2018-11-09
KR20180073680A (ko) 2018-07-02
JP2025020227A (ja) 2025-02-12
JP2018532804A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
TWI786636B (zh) 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法
CA3079946A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
KR20220035272A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP7841752B2 (ja) 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法
RU2747193C2 (ru) Композиции, содержащие антитела к il6r, для лечения увеита и макулярного отека, и способы их применения
CA3216063A1 (en) Treatment for lupus nephritis using anti-baffr antibodies
RU2853717C1 (ru) Композиции и способы лечения невоспалительной боли у субъектов с ревматоидным артритом
RU2853717C9 (ru) Композиции и способы лечения невоспалительной боли у субъектов с ревматоидным артритом
TW202608479A (zh) 治療具有類風濕性關節炎的個體中疼痛之組成物及方法